The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution

Author(s): Sathish Dyawanapelly, Vijayabhaskar Reddy Junnuthula, AkhileshVikram Singh

Journal Name: Current Drug Metabolism

Volume 16 , Issue 7 , 2015

Become EABM
Become Reviewer
Call for Editor


In recent years, multifaceted clinical benefits of polymeric therapeutics have been reported. Over the past decades, cancer has been one of the leading causes of mortality in the world. Many clinically approved chemotherapeutics encounter potential challenges against deadly cancer. Moreover, safety and efficacy of anticancer agents have been limited by undesirable pharmacokinetics and biodistribution. To address these limitations, various polymer drug conjugates are being studied and developed to improve the antitumor efficacy. Among other therapeutics, polymer therapeutics are well established platforms that circumvent anticancer therapeutics from enzymatic metabolism via direct conjugation to therapeutic molecules. Interestingly, polymer therapeutics meets an unmet need of small molecules. Further clinical study showed that polymer-drug conjugation can achieve desired pharmacokinetics and biodistribution properties of several anticancer drugs. The present retrospective review mainly enlightens the most recent preclinical and clinical studies include safety, stability, pharmacokinetic behavior and distribution of polymer therapeutics.

Keywords: Biodistribution, cancer, delivery, polymer conjugation, polymer therapeutics, pharmacokinetics.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [522 - 537]
Pages: 16
DOI: 10.2174/1389200216666141219122614
Price: $65

Article Metrics

PDF: 38